The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/89523

Please be advised that this information was generated on 2019-02-26 and may be subject to change.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, M.D., Ph.D., Claes G. Tropé, M.D., Ph.D., Frédéric Amant, M.D., Ph.D., Gunnar B. Kristensen, M.D., Ph.D., Tom Ehlen, M.D., Nick Johnson, M.D., René H.M. Verheijen, M.D., Ph.D., Maria E.L. van der Burg, M.D., Ph.D., Angel J. Lacave, M.D., Pierluigi Benedetti Panici, M.D., Ph.D., Gemma G. Kenter, M.D., Ph.D., Antonio Casado, M.D., Cesar Mendiola, M.D., Ph.D., Corneel Coens, M.Sc., Leen Verleye, M.D., Gavin C.E. Stuart, M.D., Sergio Pecorelli, M.D., Ph.D., and Nick S. Reed, M.D., for the European Organization for Research and Treatment of Cancer—Gynaecological Cancer Group and the NCIC Clinical Trials Group* — a Gynecologic Cancer Intergroup Collaboration

From the University Hospitals Leuven, Leuven (I.V., F.A.), and the European Organization for Research and Treatment of Cancer Headquarters, Brussels (C.C., L.V.) — both in Belgium; Norwegian Radium Hospital and the Institute of Medical Informatics, Oslo (C.G.T., G.B.K.); University of British Columbia, Vancouver, Canada (T.E., G.C.E.S.); Royal United Hospital, Bath (N.J.), and Gartnavel General Hospital and Beatson Oncology Center, Glasgow (G.G.K.) — both in the United Kingdom; Vrije Universiteit Medical Center, Amsterdam (R.H.M.V.), Erasmus MC University Medical Center Rotterdam, Rotterdam (M.E.L.B.), and Leiden University Medical Center, Leiden (G.G.K.) — all in the Netherlands; Hospital Universitario Central de Asturias, Oviedo, Spain (A.C.); University of Rome La Sapienza, Rome (P.B.P.), and the University of Brescia, Brescia (S.P.) — both in Italy; and Hospital Universitario San Carlos (A.C.) and Hospital Universitario 12 de Octubre (C.M.) — both in Madrid. Address reprint requests to Dr. Vergote at University Hospitals, K.U. Leuven Division of Gynecologic Oncology, Herestraat 49, B-3000 Leuven, Belgium, or at ignace.vergote@uzleuven.be.

*Other collaborators are listed in the Appendix.

In most women with ovarian carcinoma, the disease is not diagnosed until it is at an advanced stage. Primary cytoreductive surgery is considered the standard of care for advanced ovarian carcinoma. However, data from prospective, randomized, controlled trials assessing the role of primary surgery in the treatment of such cases are lacking. Interval debulking surgery has not been viewed as beneficial in women with residual tumor that exceeds 1 cm in diameter after primary debulking surgery performed with the objective of maximal surgical effort by a gynecologic oncologist. As an alternative to primary debulking surgery followed by chemotherapy, some authors have investigated the use of neoadjuvant chemotherapy before cytoreductive surgery. However, results of a meta-analysis involving 835 patients suggested that neoadjuvant chemotherapy, as compared with primary debulking surgery, was associated with a worse outcome.

We report on a randomized trial in which we compared primary debulking surgery followed by platinum-based chemotherapy and platinum-based neoadjuvant chemotherapy followed by interval debulking surgery and additional platinum-based chemotherapy in women with advanced ovarian carcinoma.

METHODS

PATIENTS

Eligible patients had biopsy-proven stage IIIC or IV invasive epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian-tube carcinoma. If a biopsy specimen was not available, a fine-needle aspirate showing an adenocarcinoma was acceptable under the following conditions: the presence of a pelvic (ovarian) mass; the presence of metastases outside the pelvis measuring at least 2 cm in diameter (as noted during diagnostic laparoscopy or laparotomy or on computed tomography [CT]); regional lymph-node metastasis or proof of stage IV disease; and a ratio of cancer antigen 125 (CA-125, measured in kilounits per liter) to carcinoembryonic antigen (CEA, measured in nanograms per milliliter) that was greater than 25. The CA-125:CEA ratio has been shown to be useful for ruling out primary gastrointestinal tumors that have metastasized to the peritoneum, the ovaries, or both. If the serum CA-125:CEA ratio was 25 or lower, results of a barium enema (or colonoscopy), gastroscopy (or radiologic examination of the stomach), and mammography (performed within 6 weeks before randomization) had to be negative for the presence of a primary tumor. Additional prerandomization requirements included a World Health Organization (WHO) performance status of 0 (asymptomatic) to 2 (symptomatic, in bed for less than half the day) and the absence of serious disabling diseases that would contraindicate primary cytoreductive surgery or platinum-based chemotherapy. (Other inclusion criteria are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.) Before receiving treatment, all patients provided written informed consent. Because of an allegation of ethical irregularities at one of the centers with regard to another European Organization for Research and Treatment of Cancer (EORTC) protocol, all the patients from that center who were enrolled in this study were excluded from the analysis.

STUDY DESIGN

Patients had to start the assigned treatment within 3 weeks after the initial biopsy or fine-needle aspiration. The biopsy could be image-guided or carried out during laparoscopy or laparotomy. Patients who underwent laparotomy or laparoscopy were not allowed to undergo any procedures other than the diagnostic biopsies. Randomization was done centrally at the EORTC headquarters after stratification, with the use of a minimization technique to stratify for institution, method of biopsy (image-guided, laparoscopy, laparotomy, or fine-needle aspiration), tumor stage (IIIC or IV), and largest preoperative tumor size (excluding ovaries) (<5 cm, >5 to 10 cm, >10 to 20 cm, or >20 cm).

Patients were randomly assigned either to primary debulking surgery followed by at least six courses of platinum-based chemotherapy or to three courses of neoadjuvant platinum-based chemotherapy followed by interval debulking surgery in all patients with a response or stable disease, followed in turn by at least three courses of platinum-based chemotherapy. In patients randomly assigned to primary debulking whose surgery was completed without optimal cytoreduction, interval debulking surgery was permitted if stable disease or a response was documented, and these patients were included in the primary-surgery group for analyses. After the results of the Gynecologic Oncology Group trial (GOG-152)
Tumor response during chemotherapy was defined by an increase by a factor of at least 2 in the nadir serum CA-125 level according to the Gynaecologic Cancer Intergroup criteria.\textsuperscript{12}

**Statistical Analysis**

The primary end point of the study was overall survival. The group undergoing primary debulking surgery was considered to be the standard-treatment group. On the basis of the earlier experience of the EORTC institutions, about 50\% of patients with stage IIBC or IV ovarian carcinoma who underwent debulking surgery had a residual tumor size of 1 cm or less and had a median survival of 36 months.\textsuperscript{13} On the basis of a previous EORTC trial of interval debulking surgery, median survival among the patients with suboptimal primary debulking who underwent interval surgery was expected to be 26 months.\textsuperscript{5} Thus, the median survival of the whole group of patients randomly assigned to primary surgery was expected to be 31 months. With an accrual time of 4 years and a minimum follow-up period of 3 years, 498 events (704 patients) were required to show noninferiority of interval debulking surgery as compared with primary surgery, with a one-sided type I error rate of 0.05 and a power of 80\%. A hazard ratio of less than 1.25 was considered to indicate noninferiority. Secondary end points were adverse effects, quality of life, and progression-free survival. No interim analyses were planned or conducted.

The analysis was planned to be performed according to the intention-to-treat principle: all randomly assigned patients were included in the primary analysis, regardless of whether they were eligible and whether they could be evaluated. A secondary analysis was based on the treatment actually received. For definitions of overall and progression-free survival, see the Supplementary Appendix. Overall and progression-free survival rates were estimated by means of the Kaplan–Meier method, and overall survival rates in the two groups were compared by means of the logrank test, with a noninferiority ratio of 0.8. Multivariate time-to-event analysis was performed with the use of a Cox proportional-hazards model and univariate screening followed by a stepwise variable-selection procedure.\textsuperscript{14} Adverse events were reported in contingency tables with the use of the National Cancer Institute Common Toxicity Criteria, version 2.0 (http://ctep.cancer.gov/protocoldevelopment/electronic_
The new england journal of medicine

718 Patients were enrolled

48 Were excluded owing to authorization irregularities

670 Underwent randomization

336 Were assigned to primary surgery
315 Received assigned intervention
21 Did not receive assigned intervention
8 (38%) Were withdrawn by physician
3 (14%) Declined to participate
3 (14%) Had different histologic diagnosis
1 (5%) Died
2 (10%) Had unresectable tumor
3 (14%) Had logistic or administrative problem
1 (5%) Had unknown reason

315 (94%) Underwent primary debulking
297 (88%) Started chemotherapy
57 (17%) Underwent interval debulking
11 (3%) Underwent second-look procedure

334 Were assigned to neoadjuvant chemotherapy
326 Received assigned intervention
8 Did not receive assigned intervention
3 (38%) Were withdrawn by physician
2 (25%) Declined to participate
1 (13%) Had different histologic diagnosis
1 (13%) Died
1 (13%) Had logistic or administrative problem

2 (1%) Underwent primary debulking
326 (98%) Started neoadjuvant chemotherapy
295 (88%) Underwent interval debulking
6 (2%) Underwent second-look procedure

310 Were included in the intention-to-treat analysis
322 Were included in the per-protocol analysis

26 Were excluded from per-protocol analysis
11 Were ineligible
1 Had FNA without pelvic mass
1 Had wrong disease stage
3 Had histologic reason
4 Had disabling disease
1 Had prior cancer
1 Had delay of >2 mo between biopsy and randomization
1 Did not give enough information to assess eligibility
14 Did not start assigned treatment

334 Were included in the intention-to-treat analysis

5 Were lost to follow-up
71 Discontinued treatment
20 (28%) Had relapse or died from cancer
11 (16%) Had excessive toxic effects
4 (6%) Declined treatment
7 (10%) Died from other causes
3 (4%) Had protocol violation
25 (35%) Had other reason
1 (1%) Reported no reason for discontinuing therapy

322 Were included in the per-protocol analysis

12 Were excluded from per-protocol analysis
6 Were ineligible
1 Had FNA without pelvic mass
2 Had FNA, CA-125:CEA ratio ≤25, and imaging not adequate to exclude other primary tumor
1 Had histologic reason
1 Had disabling disease
1 Signed consent before ethical approval
6 Did not start assigned treatment

3 Were lost to follow-up
78 Discontinued treatment
34 (44%) Had relapse or died from cancer
16 (21%) Had excessive toxic effects
1 (1%) Declined treatment
5 (6%) Died from other causes
2 (3%) Had protocol violation
18 (23%) Had other reason
2 (3%) Reported no reason for discontinuing therapy

336 Were included in the intention-to-treat analysis

Figure 1. Numbers of Patients Who Were Enrolled, Randomly Assigned to a Treatment Group, and Included in the Analyses.

CA-125 denotes cancer antigen 125, CEA carcinoembryonic antigen, and FNA fine-needle aspiration. Percentages may not total 100% because of rounding.

The New England Journal of Medicine

Copyright © 2010 Massachusetts Medical Society. All rights reserved.
Interval debulking surgery was well balanced between the two treatment groups (Table 1). Details regarding residual tumor size were well balanced between the two treatment groups (Fig. 1). The remaining 670 patients were randomly assigned to treatment at 59 institutions (median accrual per institution, 5 patients; range, 1 to 125) (Fig. 1).

The results of the study were similar whether the 48 patients from the one center with possible irregularities were included or excluded. The requisite number of events was reached in August 2008 (median follow-up, 4.7 years).

The baseline characteristics of the patients were well balanced between the two treatment groups (Table 1). Details regarding residual tumor size were well balanced between the two treatment groups (Fig. 1).

After debulking surgery, the primary diagnosis changed in 11 patients (3.3%) assigned to primary debulking surgery and in 7 patients (2.1%) assigned to neoadjuvant chemotherapy followed by interval debulking surgery (5 carcinosarcomas, 4 endometrial carcinomas, 2 gastrointestinal tumors, 2 borderline tumors of the ovary, 1 cervical adenocarcinoma, 1 stage IC ovarian carcinoma, 1 teratoma, 1 rhabdomyosarcoma, and 1 pseudomyxoma).

The diaphragm, abdominal peritoneum, and pelvis (pouch of Douglas, uterus, bladder, rectum, and sigmoid) were the most frequent sites of residual tumor after both primary debulking and interval debulking surgery. Details on the size and site of the metastases before and after primary and interval debulking surgery, as well as the debulking rates after interval debulking in patients in the primary-surgery group, are summarized in the Supplementary Appendix. Within each country, there was a strong correlation between the rates of optimal debulking at primary debulking surgery and at interval debulking surgery (r=0.92).

Overall survival was similar in the two groups in the intention-to-treat analyses (Fig. 2A), as was progression-free survival (Fig. 1 in the Supplementary Appendix). The median overall survival was 29 months in the primary-surgery group and 30 months in the neoadjuvant-chemotherapy group, and the median progression-free survival in both groups was 12 months. On the basis of the intention-to-treat analysis, the hazard ratio for death in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P=0.01 for noninferiority), and the hazard...
ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15). The analysis according to treatment actually received (per-protocol analysis) showed similar results for overall survival (hazard ratio for death, 1.00; 90% CI, 0.85 to 1.16; P = 0.01 for noninferiority) (Fig. 2 in the Supplementary Appendix). Figure 2B shows overall survival according to treatment group and amount of residual tumor (per-protocol analysis). Overall survival in the group of patients who underwent primary debulking surgery initially and then interval debulking surgery was similar to that in the group of patients who were randomly assigned to neoadjuvant chemotherapy (Fig. 3 in the Supplementary Appendix).

In a post hoc attempt to identify subgroups

<table>
<thead>
<tr>
<th>Table 1. Baseline Characteristics of the Patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristic</strong></td>
</tr>
<tr>
<td>Age — yr</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>WHO performance status — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Histologic type — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Histologic grade — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Stage — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Malignant pleural effusion — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Method of biopsy — no. (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
of patients in which one of the study treatments tended to be associated with better overall survival, we analyzed the hazard plots in relation to age, the International Federation of Gynecology and Obstetrics (FIGO) stage, WHO performance status, histologic type, and presence or absence of pleural fluid (Fig. 4 to 8 in the Supplementary Appendix). In none of the subgroups was there apparent superiority of one of the treatments.

When we evaluated the outcome of debulking to 1 cm or less according to country, no significant differences were noted between the treatment groups (Fig. 9 in the Supplementary Appendix). When the patients who were randomly assigned by the EORTC-GCG (586 patients) were compared with those randomly assigned by the NCIC Clinical Trials Group (84 patients), the median overall survival was similar (28 and 34 months, respectively). This result is noteworthy, since the proportions of patients with no residual tumor after primary debulking surgery and after interval debulking surgery tended to be higher in the subgroup randomly assigned by the EORTC-GCG (20.4% and 50.0%, respectively) than in the sub-

### Table 1. (Continued.)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Primary Debulking Surgery (N = 336)</th>
<th>Neoadjuvant Chemotherapy (N = 334)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumor — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epithelial ovarian</td>
<td>293 (87.2)</td>
<td>283 (84.7)</td>
</tr>
<tr>
<td>Peritoneal</td>
<td>22 (6.5)</td>
<td>26 (7.8)</td>
</tr>
<tr>
<td>Fallopian tube</td>
<td>0</td>
<td>4 (1.2)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>17 (5.1)</td>
<td>20 (6.0)</td>
</tr>
<tr>
<td>Missing data</td>
<td>4 (1.2)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Serum CA-125 at entry (U/ml)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>1130</td>
<td>1180</td>
</tr>
<tr>
<td>Range</td>
<td>16.0–27,185</td>
<td>15.0–41,456</td>
</tr>
<tr>
<td>Serum CA-125 &gt;30 U/ml — no. (%)</td>
<td>330 (98.2)</td>
<td>330 (98.8)</td>
</tr>
<tr>
<td>Largest metastatic tumor at randomization — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 cm</td>
<td>2 (0.6)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>&gt;0–2 cm</td>
<td>2 (0.6)</td>
<td>9 (2.7)</td>
</tr>
<tr>
<td>&gt;2–5 cm</td>
<td>90 (26.8)</td>
<td>85 (25.4)</td>
</tr>
<tr>
<td>&gt;5–10 cm</td>
<td>90 (26.8)</td>
<td>88 (26.3)</td>
</tr>
<tr>
<td>&gt;10–20 cm</td>
<td>105 (31.3)</td>
<td>113 (33.8)</td>
</tr>
<tr>
<td>&gt;20 cm</td>
<td>26 (7.7)</td>
<td>24 (7.2)</td>
</tr>
<tr>
<td>Missing data</td>
<td>21 (6.3)</td>
<td>14 (4.2)</td>
</tr>
<tr>
<td>Size of metastases at the time of surgery — no. (%)†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No metastasis</td>
<td>1/310 (0.3)</td>
<td>14/322 (4.3)</td>
</tr>
<tr>
<td>&gt;0–1 cm</td>
<td>2/310 (0.6)</td>
<td>36/322 (11.2)</td>
</tr>
<tr>
<td>&gt;1–2 cm</td>
<td>14/310 (4.5)</td>
<td>40/322 (12.4)</td>
</tr>
<tr>
<td>&gt;2–5 cm</td>
<td>50/310 (16.1)</td>
<td>74/322 (23.0)</td>
</tr>
<tr>
<td>&gt;5–10 cm</td>
<td>40/310 (12.9)</td>
<td>42/322 (13.0)</td>
</tr>
<tr>
<td>&gt;10 cm</td>
<td>191/310 (61.6)</td>
<td>78/322 (24.2)</td>
</tr>
<tr>
<td>Missing data</td>
<td>12/310 (3.9)</td>
<td>38/322 (11.8)</td>
</tr>
</tbody>
</table>

* WHO denotes World Health Organization.
† The per-protocol population included only eligible patients who actually underwent primary debulking surgery in the primary-surgery group (310 patients) and patients who actually started chemotherapy in the neoadjuvant-chemotherapy group (322).
group assigned by the NCIC Clinical Trials Group (11.1% and 40.5%, respectively). Among patients with metastatic tumors that were less than 5 cm in diameter at randomization, overall survival was slightly longer in the primary-surgery group than in the neoadjuvant-chemotherapy group (hazard ratio, 0.64; 95% CI, 0.45 to 0.93) (Fig. 10 in the Supplementary Appendix).
MULTIVARIATE ANALYSES

Unadjusted and adjusted Cox regression multivariate analyses were performed post hoc, with overall survival as the end point, and included the following variables: largest residual tumor after primary or interval debulking surgery, largest tumor size before randomization, WHO performance status, age, FIGO stage, histologic type, method of biopsy, histologic grade, treatment group, and country (reduced to eight categories by pooling results from the smallest seven countries). The strongest independent predictors of prolonged survival, in descending order, were the absence of residual tumor after surgery (P=0.001); stage IIIC disease (P=0.001); small tumor size before randomization (P=0.001); endometrioid histologic type, followed in descending order by serous, mixed, undifferentiated, mucinous, and clear-cell types (P=0.005); and younger age (P=0.005). The other variables did not significantly influence overall survival.

DISCUSSION

In this randomized trial, primary debulking surgery followed by chemotherapy was compared with neoadjuvant chemotherapy followed by interval debulking surgery in women with advanced ovarian cancer. We found that survival after neoadjuvant chemotherapy followed by interval debulking surgery was similar to survival with the standard approach of primary surgery followed by chemotherapy.

This trial did not include patients with FIGO stage IIIB or earlier-stage ovarian carcinoma. Rather, all the study participants had extensive stage IIIC or IV disease. Indeed, most patients had obvious stage IIIC or IV disease; at the time of primary debulking surgery, 61.6% had metastatic lesions that were larger than 10 cm in diameter, and 74.5% had lesions larger than 5 cm. This is noteworthy, since it might be the reason for the poor outcomes with respect to median progression-free and overall survival, as compared with the findings in some single-institution series; however, the debulking rates and survival rates in our study are similar to those in other multicenter or regional studies that analyzed stage IIIC and IV ovarian carcinomas separately. Furthermore, the current study showed no trend in favor of primary debulking in countries with high rates of optimal primary debulking surgery. This finding might be due to the strong correlation between cytoreduction rates at primary debulking surgery and at interval debulking surgery within each country.

In selecting patients for neoadjuvant chemotherapy, it is important to rule out other primary tumors, especially those of gastrointestinal origin. In this study, a CA-125:CEA ratio higher than 25 was used as an eligibility criterion, since this ratio has been shown to be a good tool for ruling out primary gastrointestinal tumors that have metastasized to the peritoneum or ovaries or to both sites. The value of this ratio was confirmed in the current study, since only two patients proved to have a gastrointestinal cancer at the time of primary or interval debulking surgery.

Complete resection of all macroscopic disease at primary debulking surgery has been shown to be the single most important independent prognostic factor in advanced ovarian carcinoma. In the current study, the importance of this prognostic factor was confirmed by the results of the multivariate analyses and the survival analyses according to the extent of residual tumor after both primary and interval debulking surgery (Fig. 2B). Given our findings and the results of other studies, a potential approach for debulking surgery could be the elimination of all macroscopic residual disease, rather than the elimination of lesions larger than 1 cm in diameter. A potential drawback of neoadjuvant chemotherapy followed by debulking surgery is that the occurrence of fibrosis after chemotherapy may make complete resection of macroscopic disease more difficult.

In conclusion, among patients with advanced (stage IIIC or IV) ovarian, fallopian-tube, or peritoneal ovarian carcinoma, survival after neoadjuvant chemotherapy followed by interval debulking surgery is similar to survival after primary debulking surgery followed by chemotherapy. This result is consistent with the conclusions of a recent meta-analysis of 21 nonrandomized trials. The standard of care for women with stage IIIB or earlier-stage epithelial ovarian cancer — a group with a better prognosis than the current study population — remains primary cytoreductive surgery. Only those patients with proven stage IIIC or IV disease should be considered for neoadjuvant chemotherapy.

In the current study, none of the subgroup
analyses showed a significant difference in survival between the two treatment groups. When deciding whether a patient is a candidate for primary debulking surgery, with an acceptable level of morbidity, the clinician may consider taking into account information from the surgical consultation and could assess important predictive factors with respect to residual macroscopic disease after debulking surgery (e.g., presence or absence of coexisting illnesses, age, disease burden, location of metastatic sites, WHO performance status, and tumor stage). Laparoscopy, in addition to axial CT, positron-emission tomography, or both, may provide information about the disease burden. Neoadjuvant chemotherapy is not inferior to primary cytoreductive surgery for patients with stage IIIC or IV ovarian carcinoma. No significant advantages of neoadjuvant therapy or primary debulking surgery were observed with respect to survival, adverse effects, quality of life, or postoperative morbidity or mortality.

The views expressed in this article are those of the authors and do not necessarily reflect the official views of the National Cancer Institute.

Supported by grants (2U10 CA11488-28 through 2U10 CA011488-36) from the National Cancer Institute and by a donation from Vlaamse Liga Tegen Kanker (the Flemish League against Cancer) to the EORTC Charitable Trust.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

APPENDIX

In addition to the authors, the following EORTC–GCG and NCIC Clinical Trials Group collaborators participated in the study: R. Angiolii (Università Campus BioMedico di Roma, Rome), J. Bentley (Nova Scotia Cancer Centre, Halifax, Canada), P. Berteloot (University Hospital Leuven, Leuven, Belgium), P. Bessette (Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada), K. Boman (Umeå University, Umeå, Sweden), M. Buist (Academic Medical Center, Amsterdam), K. Chan (Hôpital Charles Lemanone, Longueuil, QC, Canada), S. Chan (Nottingham City Hospital, Nottingham, United Kingdom (UK)), L. De Rouck, L. Giurgea, G. Hoctin-Boes, I. Teodorovic, K. Ven, I. Van Luijk. NCIC Clinical Trials Group Headquarters, C.W.M. Wensveen (Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands), P. Zola (Ospedale Mauriziano, Genova (Universitä Ziekenhuis Antwerpen, Antwerp, Belgium), J.A. Vidart Aragon (Hospital Universitario San Carlos, Madrid), R. Counsell (Cheltenham General Hospital, Cheltenham, UK), D.J. Cruickshank (James Cook University Hospital, Middlesbrough, UK), J. Davis (Gartnavel General Hospital and Beatson Oncology Center, Gynaecological Oncology, Glasgow, UK), J. De Greve (Universiteit Ziekenhuis Brussel, Brussels), C.F. De Trizio (Hospitais sa Universidade de Coimbra, Coimbra, Portugal), B. De Valk (Onze Lieve Vrouwen Gasthuis, Amsterdam), C. Dittrich (Kaiser Franz Josef Spital, Vienna), L. Elit (Helmholtz Health Sciences, Juvaringen Cancer Centre, Hamilton, ON, Canada), G. Favalli (Ospedale Santa Maria Delle Croci, Ravenna, Italy), A. Flequot (Insitut Bergonie, Bordeaux, France), P. Gauthier (Hôpital Notre-Dame du CHUM, Montreal), E. Gerdin (Akademiska Sjukhuset, Uppsala, Sweden), P. Ghatage (Tom Baker Cancer Centre, Calgary, AB, Canada), E. Gilby (Royal United Hospital, Bath, UK), N. Gleeson (Coombe Women’s Hospital, Dublin), W. Gottlieb (McGill University, Montreal), J.A. Green (Clatterbridge Center for Oncology National Health Service Trust, Liverpool, UK), R. Grimshaw (Nova Scotia Cancer Centre, Halifax, Canada), M. Heywood (CancerCare Manitoba, Winnipeg, Canada), V. Hirsch (McGill University, Montreal), K. Hoekman (Vrije Universiteit Medical Center, Amsterdam), A. Honkoop (Sophia Ziekenhuis, Zwolle, the Netherlands), P. Hoskins (British Columbia Cancer Agency (BCCA)–Vancouver Cancer Centre, Vancouver, BC, Canada), P. Kannisto (Lund University Hospital, Lund, Sweden), R. Katsaros (Clinica Universita, Turin, Italy), K. Kieser (Nova Scotia Cancer Centre, Halifax, Canada), T.V. Kristeller (I.P.O. Francisco Gentil Centro de Lisboa, Lisbon, Portugal), E. Leblanc (Centre Oscar Lambret, Lille, France), J. Ledermann (University College Hospital, London), K. Leuen (University Hospital Leuven, Leuven, Belgium), R. Lotocki (CancerCare Manitoba, Winnipeg, Canada), T. Magnigo (Mirano General Hospital–Veneto, Mirano, Italy), C. Marth (Innsbruck Universitätsklinik, Innsbruck, Austria), L. Martin (BCCA–Fraser Valley Cancer Centre, Surrey, BC, Canada), L. Massuger (Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands), D. Miller (BCCA–Vancouver Cancer Centre, Vancouver, BC, Canada), B. Mosgaard (Herlev Hospital–University of Copenhagen, Copenhagen), F. Mota (Hospita da Universidade de Coimbra, Coimbra, Portugal), P. Neven (University Hospital Leuven, Leuven, Belgium), M. Nooij (Leiden University Medical Center, Leiden, the Netherlands), R. Nordal (Haukeland Hospital–University of Bergen, Bergen, Norway), A. Nordin (Queen Elizabeth, the Queen Mother Hospital, Margate (Kent), UK), P.B. Ottevanger (Radboud University Nijmegen, Nijmegen), F. Mota (Hospitais da Universidade de Coimbra, Coimbra, Portugal), P. Neven (University Hospital Leuven, Leuven, Belgium), M. Nooij (Leiden University Medical Center, Leiden, the Netherlands), R. Nordal (Haukeland Hospital–University of Bergen, Bergen, Norway), A. Nordin (Queen Elizabeth, the Queen Mother Hospital, Margate (Kent), UK), P.B. Ottevanger (Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands), A. Papadopoulos (Mid Kent Oncology Centre, Maidstone (Kent), UK), E. Petru (Medical University of Graz, Graz, Austria), M. Plante (Centre Hospitalier de l’Université de Québec–Pavillon Hotel-Dieu de Québec, Quebec City, QC, Canada), C. Popadiuk (Dr. H. Bliss Murphy Cancer Centre, St. John’s, NF, Canada), D. Provencher (Hôpital Notre-Dame du Centre Hospitalier de l’Université de Montréal, Montreal), C. Redman (North Staffordshire Hospital, Staffordshire, UK), K.J. Rozendaal (Onze Lieve Vrouwen Gasthuis, Amsterdam), G. Rustin (Mount Vernon Hospital, Northwood, Middlesex, UK), A.H. Sadozye (Gartnavel General Hospital, Glasgow, UK), R. Sandvei (Haukeland University Hospital, Bergen, Norway), J.M. Seoane (Universitario 12 de Octubre, Madrid), M.I. Sereni (Campus BioMedico, University of Rome, Rome), S. Sert (Norwegian Radium Hospital, Oslo), N. Siddiqui (Royal Infirmary, University of Glasgow, Glasgow, UK), P. Speis (Allgemeines Krankenhaus der Stadt Wien, Vienna), B. Tholander (Karolinska University Hospital, Stockholm), G. Tognon (Universita di Brescia, Brescia, Italy), B. Trimboe (Leiden University Medical Center, Leiden, the Netherlands), M. Trudeau (McGill University, Montreal), M. Van Baal (Vrije Universiteit Medisch Centrum, Amsterdam), H.C. Van Doorn (Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands), J. Van Der Velden (Academisch Medisch Centrum, Amsterdam), K. Van Eysen (AZ Groeningh, Campus Maria’s Voorzienigheid, Kortrijk, Belgium), J.B. Vermarken (Universitair Ziekenhuis Antwerpen, Antwerp, Belgium), J.A. Vidart Aragon (Hospital Universitario San Carlos, Madrid), C.W.M. Wensveen (Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands), P. Zola (Ospedale Mauriziano Umberto I, Turin, Italy), EORTC Headquarters, Brussels — A. Anastopoulosou, U. Bethe, K. Dehaes, A. Demeester, G. Demonty, E. De Heusch, M. De Rouck, L. Giurgea, G. Hoctin-Boes I. Teodorovic, K. Ven, I. Van Luijk. NCIC Clinical Trials Group Headquarters, Queen’s University, Kingston, ON, Canada — M. Bacon, E. Eisenhauer.
REFERENCES

13. Chi DS, Eisenhauer EL, Land J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.
18. Chi DS, Eisenhauer EL, Land J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.